Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Global pharmaceutical company Merck (NYSE:MRK) in Q3 CY2025, with sales up 3.7% year on year to $17.28 billion. The company ...

Merck (MRK) delivered annual earnings growth of 19.4%, outpacing its own 5-year average growth rate of 13.4%. Profit margins ...

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid ...

Keytruda remains a major growth driver, with Q2 revenue up 9% year over year, but its looming loss of exclusivity is ...

Merck & Co Inc (MRK) reports a 4% revenue increase driven by Keytruda's demand, while facing headwinds in Gardasil sales and competitive pressures.

Merck & Co. is starting construction on a $3 billion pharmaceutical manufacturing facility in Elkton that is expected to ...

While the M&A emphasis is currently on life sciences, a business unit which sells products used in R&D and manufacturing facilities, the healthcare business could also see further deals, particularly ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access . * Reflecting concerns, ...

Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life ...

The company will begin its domestic investment by starting construction on a $3 billion pharmaceutical manufacturing site in ...

WHITEHOUSE STATION, N.J., March 1, 2010 - Merck & Co., Inc. announced today that it has been advised by AstraZeneca PLC that it will exercise the option to obtain Merck's interest in AstraZeneca's non ...